SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) today announced that new data presented at the 2023 American Thyroid Association (ATA) Annual Meeting demonstrate the type of novel molecular insights for thyroid nodules and cancer that are enabled by analysis with the Afirma Genomic Sequencing Classifier (GSC).

南旧金山，加利福尼亚州-（商业电线）-Veracyte，Inc。（纳斯达克股票代码：VCYT）今天宣布，2023年美国甲状腺协会（ATA）年会上提交的新数据证明了甲状腺的新型分子见解类型通过Afirma基因组测序分类器（GSC）分析可以实现结节和癌症。

Presented by clinical researchers in three posters, the findings are based on Afirma whole-transcriptome RNA sequencing data and reveal novel molecular profiles to advance research of thyroid nodules and cancer. These data represent findings that can be assessed utilizing the company’s Afirma Genomic Resource for Intelligent Discovery (GRID) tool, which will soon be available, upon request, on a research-use-only basis..

临床研究人员在三张海报上发表的研究结果基于Afirma全转录组RNA测序数据，揭示了新的分子谱，以推进甲状腺结节和癌症的研究。这些数据代表的发现可以利用该公司的Afirma Genomic Resource for Intelligent Discovery（GRID）工具进行评估，该工具将很快根据要求仅在研究用途的基础上提供。。

“These ATA presentations underscore the value of personalized, whole-transcriptome-based data for a clearer understanding of the molecular underpinnings of thyroid nodules and cancer, which may ultimately be useful for more tailored treatment of patients,” said Joshua Klopper, M.D., Veracyte’s medical director for Endocrinology.

Veracyte内分泌学医学主任Joshua Klopper博士说：“这些ATA演示强调了个性化，基于全转录组的数据的价值，可以更清楚地了解甲状腺结节和癌症的分子基础，这最终可能对更具针对性的患者治疗有用。”。

“Now with the Afirma GRID, we are pleased to give researchers a new tool to help fuel novel discoveries in the science of thyroid nodules and cancer.”.

“现在使用Afirma网格，我们很高兴为研究人员提供一种新工具，帮助推动甲状腺结节和癌症科学的新发现。”。

The three ATA posters include results from the analysis of whole-transcriptome data derived from the Afirma GSC. Highlights from the posters include:

三个ATA海报包括来自Afirma GSC的整个转录组数据的分析结果。海报的亮点包括：

Leveraging RNA Sequencing for Pre-Operative Immunophenotyping of BRAFV600E+ Thyroid Nodules

利用RNA测序对BRAFV600E+甲状腺结节进行术前免疫分型

Jarod Olay, M.S., from the UCLA David Geffen School of Medicine and collaborators found that RNA expression profiles derived by Afirma GSC molecular testing may allow for pre-operative immunophenotyping of thyroid cancers instead of the traditional immunohistochemistry performed on surgical specimens.

来自加州大学洛杉矶分校David Geffen医学院和合作者的Jarod Olay，M.S。发现，通过Afirma GSC分子检测获得的RNA表达谱可以允许甲状腺癌的术前免疫表型分析，而不是对手术标本进行传统的免疫组化。

Their study was based on a retrospective analysis of nearly 48,000 thyroid nodules analyzed with the Afirma GSC, confirming that the classifier identified the expected immunophenotype for a specific type of thyroid cancer molecular alteration. While additional research is needed, these findings begin to suggest the potential future use of Afirma GSC testing to predict a thyroid cancer’s response to immune checkpoint inhibitor therapy..

他们的研究基于对Afirma GSC分析的近48000个甲状腺结节的回顾性分析，证实分类器确定了特定类型的甲状腺癌分子改变的预期免疫表型。虽然需要进一步的研究，但这些发现开始表明未来可能使用Afirma GSC检测来预测甲状腺癌对免疫检查点抑制剂治疗的反应。。

Molecular Assessment of Isthmus Thyroid Carcinomas

峡部甲状腺癌的分子评估

Sina Jasim, M.D., from Washington University in St. Louis and collaborators detected molecular differences between thyroid cancers in the isthmus compared to lobar locations, which could help explain why thyroid nodules in the isthmus are more likely to be malignant and demonstrate aggressive behavior.

来自圣路易斯华盛顿大学的Sina Jasim博士及其合作者发现峡部甲状腺癌与肺叶位置之间存在分子差异，这可能有助于解释为什么峡部甲状腺结节更可能是恶性的并表现出攻击性行为。

Analysis with Afirma GSC revealed that isthmus-based cancers had increased BRAF-like molecular signatures, ERK, and FMT (follicular mesenchymal transition) signaling compared to lobar-based cancers..

Afirma GSC分析显示，与基于肺叶的癌症相比，基于峡部的癌症具有增加的BRAF样分子特征，ERK和FMT（滤泡间质转化）信号传导。。

Sodium Iodide Symporter (NIS) Expression in Cytologically Indeterminate and Malignant Thyroid Nodules

碘化钠转运体（NIS）在细胞学不确定和恶性甲状腺结节中的表达

Prasana Santhanam, M.B.B.S., M.D., from the Johns Hopkins University School of Medicine and collaborators found that NIS expression varies widely across thyroid nodule cytological classification groups and across molecular alterations. They analyzed Afirma GSC gene expression data from more than 47,000 thyroid nodules and recommend follow-up studies to determine how pre-operative assessment of NIS expression could be used to improve treatment selection for patients..

来自约翰霍普金斯大学医学院和合作者的Prasana Santhanam，M.B.B.S.，M.D。发现NIS表达在甲状腺结节细胞学分类组和分子改变中差异很大。他们分析了来自47000多个甲状腺结节的Afirma GSC基因表达数据，并建议进行随访研究，以确定如何使用NIS表达的术前评估来改善患者的治疗选择。。

“Understanding the broad range of molecular profiles associated with thyroid cancer will require sophisticated analysis tools and studies to determine how these profiles can potentially be used to stratify patients and identify the best course of treatment,” said Dr. Santhanam. “Our team was pleased to collaborate with the Afirma team for whole-transcriptome analysis of thyroid FNA samples and to gain new insights into the spectrum of NIS expression.”.

Santhanam博士说：“了解与甲状腺癌相关的广泛分子谱将需要复杂的分析工具和研究，以确定如何将这些谱潜在地用于对患者进行分层并确定最佳治疗方案。”。“我们的团队很高兴与Afirma团队合作进行甲状腺FNA样本的全转录组分析，并获得有关NIS表达谱的新见解。”。

New Research-Use-Only Afirma GRID

新研究仅使用Afirma网格

The three molecular signatures identified in these studies, along with many other thyroid cancer molecular profiles, will soon be available through the new Afirma GRID research-use-only tool. The database was developed through novel discovery work at Veracyte and through the utilization of published literature.

这些研究中确定的三个分子特征以及许多其他甲状腺癌分子谱将很快通过新的Afirma网格研究仅使用工具获得。该数据库是通过Veracyte的新发现工作和利用已发表的文献开发的。

It is designed to serve as a comprehensive resource for research into molecular characteristics that may ultimately help improve the understanding of how to manage patients with thyroid nodules. The tool is available upon request and is intended for use on a research-use-only basis for thyroid nodules that are deemed suspicious for cancer by the Afirma GSC or are reported as Bethesda V or VI by cytopathology..

它旨在作为研究分子特征的综合资源，最终有助于提高对如何管理甲状腺结节患者的理解。该工具可应要求提供，仅用于Afirma GSC认为可疑癌症或细胞病理学报告为Bethesda V或VI的甲状腺结节的研究用途。。

“We are excited to soon make this new tool available to the thyroid cancer research community,” said Dr. Klopper. “Similar to what Veracyte has done for prostate cancer research with our Decipher GRID tool, with Afirma GRID we aim to help usher in a new era of more personalized diagnosis and treatment for patients with thyroid nodules and cancer.”.

Klopper博士说：“我们很快就可以将这种新工具提供给甲状腺癌研究界。”。“类似于Veracyte使用我们的Decipher网格工具为前列腺癌研究所做的工作，Afirma网格我们旨在帮助开创甲状腺结节和癌症患者更个性化诊断和治疗的新时代。”。

About Veracyte

关于Veracyte

Veracyte (Nasdaq: VCYT) is a global diagnostics company whose vision is to transform cancer care for patients all over the world. We empower clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Our high-performing tests enable clinicians to make more confident diagnostic, prognostic, and treatment decisions for some of the most challenging diseases such as thyroid, prostate, breast, bladder and lung cancers, as well as interstitial lung diseases.

Veracyte（纳斯达克股票代码：VCYT）是一家全球诊断公司，其愿景是改变全球患者的癌症治疗。我们赋予临床医生高价值的见解，他们需要指导和确保患者在比赛中的关键时刻诊断和治疗癌症。我们的高性能测试使临床医生能够为一些最具挑战性的疾病（如甲状腺癌，前列腺癌，乳腺癌，膀胱癌和肺癌）以及间质性肺病做出更有信心的诊断，预后和治疗决策。

We help patients avoid unnecessary procedures and speed time to diagnosis and appropriate treatment. In addition to making our tests available in the U.S. through our central laboratories, we also aim to deliver our tests to patients worldwide through a distributed model to laboratories that can perform them locally.

我们帮助患者避免不必要的手术，加快诊断和适当治疗的时间。除了通过我们的中央实验室在美国提供我们的测试之外，我们还旨在通过分布式模型向全世界的患者提供我们的测试，以便可以在当地执行它们的实验室。

For more information, please visit www.veracyte.com and follow the company on Twitter (@veracyte)..

欲了解更多信息，请访问www.veracyte.com并在Twitter（@veracyte）上关注该公司。。

Cautionary Note Regarding Forward-Looking Statements

关于前瞻性陈述的警示

This press release contains forward-looking statements, including, but not limited to our statements related to our plans, objectives, expectations (financial and otherwise) or intentions with respect to our clinical tests in and outside of the United States. Forward-looking statements can be identified by words such as: “appears,” 'anticipate,' 'intend,' 'plan,' 'expect,' 'believe,' 'should,' 'may,' 'will,' “positioned,” “designed” and similar references to future periods.

本新闻稿包含前瞻性声明，包括但不限于我们与我们在美国内外进行临床试验的计划，目标，期望（财务和其他）或意图相关的声明。前瞻性陈述可以用以下词语来标识：“出现”，“预期”，“打算”，“计划”，“期望”，“相信”，“应该”，“可能”，“将会”，“定位”，“设计”以及对未来时期的类似引用。

Examples of forward-looking statements include, among others, that the Afirma GRID can help enable clearer understanding of the molecular underpinnings of thyroid nodules and cancer, which may ultimately be useful for more tailored treatment of patients with cancer; the Afirma GRID can help researchers fuel novel discoveries in the science of thyroid nodules and cancer; Afirma GSC testing may have potential in the future to predict a thyroid cancer’s response to immune checkpoint inhibitor therapy.

前瞻性陈述的例子包括，Afirma网格可以帮助更清楚地了解甲状腺结节和癌症的分子基础，这可能最终有助于更有针对性地治疗癌症患者；Afirma网格可以帮助研究人员推动甲状腺结节和癌症科学的新发现；Afirma GSC测试可能在未来预测甲状腺癌对免疫检查点抑制剂治疗的反应。

Additional factors that may impact these forward-looking statements can be found under the caption “Risk Factors” in our Annual Report on Form 10-K filed on March 1, 2023, and our Quarterly Report on Form 10-Q filed for the three months ended June 30, 2023. Copies of these documents, when available, may be found in the Investors section of our website at https://investor.veracyte.com.

可能影响这些前瞻性陈述的其他因素可以在我们于2023年3月1日提交的表格10-K年度报告和我们提交的三份表格10-Q季度报告的标题“风险因素”下找到。截至2023年6月30日的月份。这些文件的副本（如果有）可以在我们网站的投资者部分找到https://investor.veracyte.com.

These forward-looking statements speak only as of the date hereof and, except as required by law, we specifically disclaim any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise..

这些前瞻性声明仅在本协议签署之日起生效，除法律要求外，我们明确否认有任何义务更新这些前瞻性声明或实际结果可能因新信息，未来而有所不同的原因事件或其他。。

Veracyte, the Veracyte logo and Afirma are registered trademarks of Veracyte, Inc. and its subsidiaries in the U.S. and selected countries.

Veracyte，Veracyte徽标和Afirma是Veracyte，Inc.及其子公司在美国和选定国家/地区的注册商标。

Veracyte delivers the Afirma Genomic Sequencing Classifier and TERT DNA analysis from its CLIA laboratory. These tests are not CE-IVD marked and have not been cleared or approved by the FDA; their performance characteristics were determined by Veracyte and they might be considered for Research Use Only in some markets.

Veracyte从其CLIA实验室提供Afirma基因组测序分类器和TERT DNA分析。这些测试没有CE-IVD标记，也没有被FDA批准或批准；他们的表现特征由Veracyte决定，他们可能只考虑在某些市场进行研究。

Please contact Veracyte for confirmation..

请联系Veracyte确认。。